This week we begin the episode by discussing MONALEESA-7 and why ribociclib has been shown to increase overall survival while palbociclib has not. We finish the episode with an in-depth interview with Dr. Stacie Dusetzina of Vanderbilt University on her work in pharmacoeconomics, specifically we discuss her work on the market value of cancer drugs. 

MONALEESA-7: doi.org/10.1056/NEJMoa1903765
Free drug samples are a marketing tool: doi.org/10.2105/AJPH.2007.114249 

Back us on Patreon! www.patreon.com/plenarysession

1.68 Voxeletor with Dr. Olson & Humanizing Cancer, Defining Cancer, and more with Dr. David Steensma

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com